

Giant Cell Arteritis

## A study for patients with Giant Cell Arteritis (GCA)

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

**Trial Status**  
Completed

**Trial Runs In**  
15 Countries

**Trial Identifier**  
NCT01791153 2011-006022-25  
WA28119

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA. The study will consist of 2 parts: a 52-week double-blind treatment period (Part 1) followed by a 104-week open label long-term follow-up period (Part 2). In Part 1 of the study eligible participants will be randomized to receive either tocilizumab every week (qw) or every 2 weeks (q2w) or placebo for 52 weeks, with tapering oral daily doses of prednisone. After Week 52, participants in remission will stop study treatment and enter long-term follow-up, whereas participants with disease activity or flares will receive open-label tocilizumab or other treatment at the discretion of the investigator for a maximum period of 104 weeks.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

**NCT01791153 2011-006022-25 WA28119**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥50 Years

**Healthy Volunteers**  
No